Summary
Updated Aug 31, 2026
Jean Jacques Bienaime is Director of Keros Therapeutics, Inc. (KROS). 20 SEC Form 4 filings on record going back to 2025, most recently on 19 August 2026. Most recent open-market trade: bought $10K of KROS on 19 August 2026. Lifetime open-market purchases: $1.17M. Lifetime open-market sales: $204K. Historical track record: 2/5 stars across 9 tracked purchases.
Recent Transactions
20Every recent SEC Form 4 transaction Jean Jacques Bienaime has reported, most recent first.
Track Record
InsiderAlpha computes a forward-return-based score for every insider with enough Form 4 purchase history. The metrics below reflect realized performance after each tracked open-market purchase.
| Metric | Value |
|---|---|
| InsiderAlpha rating | ★★☆☆☆ (2/5) |
| Total purchases tracked | 9 |
| Purchases with forward-return data | 9 |
| 30-day win rate | 56% |
| 90-day win rate | 56% |
| Avg 5-day return | -2.73% |
| Avg 30-day return | +0.23% |
| Avg 90-day return | -1.34% |
| Best 30-day return | +10.57% |
Trading Pattern
InsiderAlpha's records for Jean Jacques Bienaime go back to 2025: 20 primary Form 4 filings, an average of 10.0 per year. The typical open-market purchase is $59K (20 buys totaling $1.17M). The largest single buy on record is $270K of ASND in 2026. Sales side: 2 recorded sales totaling $204K, so the filing history runs buy-heavy by dollar value. 9 recorded transactions carry a Rule 10b5-1 flag, meaning they were pre-scheduled under a written trading plan rather than discretionary.
Other Insiders Active in the Same Stocks
Insiders who reported open-market trades in the last 12 months at the companies Jean Jacques Bienaime files at. Multiple unrelated insiders buying the same stock within a short window, cluster buying, has historically been one of the strongest Form 4 signals.
- ADAR1 Capital Management, LLC - $95.66M of KROS open-market activity in the last 12 months
- Pontifax Management 4 G.P. (2015) Ltd. - $84.98M of KROS open-market activity in the last 12 months
- Isaac Barchas - $9.94M of IMNM open-market activity in the last 12 months
- Flemming Steen Jensen - $4.64M of ASND open-market activity in the last 12 months
- Max Rosett - $2.52M of IMNM open-market activity in the last 12 months
- Robert Lechleider - $2.34M of IMNM open-market activity in the last 12 months
More Notable Insiders
Other corporate insiders with significant SEC Form 4 track records on InsiderAlpha:
Frequently Asked Questions
Who is Jean Jacques Bienaime?
Jean Jacques Bienaime is a corporate insider, tracked as Director of Keros Therapeutics, Inc. (KROS). InsiderAlpha holds 20 primary Form 4 filings for them, the earliest from 2025, updated as new SEC EDGAR filings are processed.
How many SEC Form 4 filings has Jean Jacques Bienaime submitted recently?
8 primary Form 4 filings in the last 90 days, covering 4 companies.
Has Jean Jacques Bienaime been buying or selling stock?
Recorded transactions: 20 open-market purchases ($1.17M) and 2 open-market sales ($204K) across all tracked filings.
How accurate is Jean Jacques Bienaime's historical track record?
Across 9 tracked purchases, Jean Jacques Bienaime averaged +0.2% avg 30-day return with a 56% 30-day win rate. InsiderAlpha rates the track record at 2/5 stars.
Where can I see all of Jean Jacques Bienaime's SEC filings?
All Form 4 filings, transaction values, and 10b5-1 plan flags are listed on this page and updated in real time as new SEC EDGAR filings are processed.
Learn More
Follow Jean Jacques Bienaime and every insider like them
A free account opens the full scored daily plan and every past day, a watchlist for any ticker, and 3 months of price history on every company page. No card.
Free plan available · Paid plans start with a 7-day free trial